Treatment with subcutaneous apomorphine will be initiated according to the usual procedures at each centre. Once the patient is included in the study, he/she will be followed for 24 months according to a schedule of visits corresponding to his/her follow-up care.

The procedures outside of the patient's usual care are only more in-depth clinical assessments and examinations (interviews with a nurse, skin lesion assessment scale, quality of life scales, neurological and cognitive assessment scales).

At each visit, the patient will be seen in consultation by a state-qualified nurse from the neurology department who will conduct

• nursing interviews to assess tolerance and compliance with treatment. She will also look for data concerning the flow rate, the duration of the subcutaneous apomorphine pump and the injection methods (material used, rotation of injection sites, massages).
• collection of adverse effects and changes in concomitant treatments.
• assessment of skin complications (number, location, characteristics: size, pain, inflammation).

For centres that do not have a nurse dedicated to monitoring these patients, the above procedure will be carried out by the neurologist.

In all cases, the patient will receive a consultation (in the department or remotely) by the neurologist.

The tests and scales performed at inclusion will be repeated at each six-monthly visit.

Inclusion Criteria:

• Age greater than or equal to 18 years,
• Diagnosis of Parkinson's disease according to the MDS criteria (2015),
• Patients with a prescription for subcutaneous apomorphine pump therapy,
• Patient having read and understood the information letter and having expressed oral non-opposition to the research.

Exclusion Criteria:

• Patient unable to express opposition or non-opposition,
• Patient not affiliated to the social security system,
• Pregnant woman or woman in labour or breastfeeding,
• Person deprived of liberty by an administrative or judicial decision,
• Person placed under court protection, guardianship or curatorship.

Patients with Parkinson's disease treated with apomorphine pumps